e.g. mhealth
Search Results (1 to 10 of 84 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 42 JMIR Dermatology
- 12 Journal of Medical Internet Research
- 9 JMIR Cancer
- 7 JMIR mHealth and uHealth
- 6 JMIR Research Protocols
- 3 Iproceedings
- 2 JMIR Formative Research
- 2 JMIR Medical Informatics
- 1 JMIR Infodemiology
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Public Health and Surveillance
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Using AI for these purposes may improve the efficiency of melanoma detection and increase population access to dermatological assessment, particularly as improvements in the precision of imaging technology and convolutional neural networks allow for more machine autonomy in decision-making, thereby changing or creating new clinical paradigms in melanoma detection.
JMIR Dermatol 2025;8:e63923
Download Citation: END BibTex RIS
Minimal research exists on Chat GPT’s accuracy in detecting melanoma. Given that patients are increasingly presenting internet-derived diagnostics during cancer consultations, it is imperative to understand the capabilities of commonly used AI engines, such as Chat GPT [4]. In this study, we compare the capabilities of two models—Chat GPT-4 Omni (GPT-4o) and Chat GPT-4 Turbo (GPT-4 Turbo)—in identifying melanoma versus “not melanoma” skin lesions.
JMIR Dermatol 2025;8:e67551
Download Citation: END BibTex RIS
Anti-MDA5+DM-ILD: melanoma differentiation–associated gene 5 antibody–positive dermatomyositis–associated interstitial lung disease; CTD: connective tissue disease.
J Med Internet Res 2025;27:e62836
Download Citation: END BibTex RIS
Furthermore, these AEs have shown to affect physical and psychosocial well-being of patients with melanoma [10-13]. Most prevalent in patients with melanoma undergoing immunotherapy with ICIs are cancer-related fatigue (CRF) and emotional distress, affecting both health-related quality of life (HRQo L) and clinical outcome to immunotherapy [8,14-16].
JMIR Cancer 2025;11:e58938
Download Citation: END BibTex RIS
Members of the public with a history of skin cancer were included in the patient group, with additional patients approached via Melanoma Focus (a UK melanoma charity that provides information, guidance, and support for patients, carers, and HCPs) [16]. GPs and primary care NPs were identified through the Primary Care Dermatology Society [17], with additional GPs approached via Sermo (medical market-research organization) [18].
JMIR Cancer 2025;11:e60653
Download Citation: END BibTex RIS
A secondary objective of the study is to assess any agreements or differences in the results of our wide range of participants in the usability studies, considering the target population of our e Health intervention (patients with melanoma and renal cell carcinoma treated with immunotherapy) and participants that are part of a broader population (patients with cancer with other types of cancer and informal caregivers).
JMIR Form Res 2025;9:e57659
Download Citation: END BibTex RIS
In recent years, the prognosis of melanoma, one of the most aggressive forms of skin cancer, has significantly improved due to advancements in innovative treatments such as immunotherapy and targeted therapy [1]. With an estimated worldwide total of 325,000 new cases in 2022, increasing to an expected total of 510,000 new cases in 2040 [2], this results in an expanding cohort of melanoma survivors, ie, individuals living with or beyond melanoma [3].
JMIR Cancer 2025;11:e55746
Download Citation: END BibTex RIS
However, a gap exists in the determinants of research participation in dermatology trials and melanoma surveillance in particular.
JMIR Dermatol 2024;7:e58136
Download Citation: END BibTex RIS
JMIR Dermatology’s 2023 Year in Review
Implementation barriers revolved around participants’ perceptions of melanoma recurrence risk. Concerns included the short time interval between melanoma diagnosis, treatment, and the introduction of the SSE model; medical provider availability for urgencies; and the need for evidence on the efficacy of SSE relative to usual care. Follow-up studies could explore underserved communities where access to dermatologic care is a preexisting limitation.
JMIR Dermatol 2024;7:e57007
Download Citation: END BibTex RIS
Melanoma is a skin cancer that has differences in outcomes based on patient demographics [2,3]; thus, it is important to understand the treatments reported in case reports and their demographic variations. Therefore, we assessed the demographics represented in melanoma case reports, the various treatment modalities listed, and how treatments vary by demographics.
To explore the demographics of patients in Pub Med-listed case reports, we used techniques previously described [1,4].
JMIR Dermatol 2024;7:e56684
Download Citation: END BibTex RIS